Allogene Therapeutics reports strong financial position and key clinical milestones following its Q4 and full-year 2025 results. The company ended the quarter with $258.3 million in cash, cash equivalents, and investments, extending its runway into Q1 2028 through disciplined spending and strategic funding.
Financial Highlights
Research and development expenses totaled $28.6 million in Q4 2025, down from prior periods, while general and administrative costs reached $13.8 million. Full-year net loss stood at $190.9 million, or $0.87 per share. For 2026, operating cash expenses are projected at around $150 million, with GAAP operating expenses near $210 million, including non-cash stock-based compensation.
Pivotal ALPHA3 Trial Advances
The Phase 2 ALPHA3 trial evaluates cemacabtagene ansegedleucel (cema-cel) for first-line consolidation in large B-cell lymphoma (LBCL). This randomized study tests early, minimal residual disease (MRD)-guided intervention to prevent relapse. Enrollment spans over 60 sites, including community centers, to broaden access.
An interim futility analysis is set for April 2026, assessing MRD clearance rates in 12 patients per arm (cema-cel post-lymphodepletion vs. observation), alongside safety and enrollment data. Positive results could demonstrate 25-30% higher MRD clearance with cema-cel, supporting scalable allogeneic CAR T delivery.
ALLO-329 Progress in Autoimmune Diseases
ALLO-329, a dual CD19/CD70 CAR T using Dagger technology for targeted lymphodepletion, advances in the Phase 1 RESOLUTION trial. This basket study targets conditions like systemic lupus erythematosus and scleroderma, testing doses from 20 million CAR T cells with reduced or no conventional lymphodepletion.
Proof-of-concept data, including biomarkers, expansion, and early outcomes, is expected in June 2026.
Other Pipeline Updates
ALLO-316 shows promising responses in renal cell carcinoma via the TRAVERSE trial, with Phase 1b enrollment complete. The company explores partnerships to further develop this asset.
Leadership Perspective
“Allogene is approaching a pivotal inflection point, with the first interim data of cema-cel’s ALPHA3 trial just weeks away,” stated David Chang, M.D., Ph.D., President, CEO, and Co-Founder. “We believe that this trial… has the potential to mark one of the most significant advances in the field in decades.”
The focus remains on scalable CAR T programs across oncology and autoimmune indications, backed by a solid financial foundation.
